• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

November 3, 2016

Trending News Today: Link Between Cancer Drugs and Cardiovascular Problems

Author(s):

Lauren Santye, Assistant Editor

Top news of the day from across the health care landscape.

The increasing heroin and opioid abuse epidemic does not appear to being slowing down anytime soon. In an effort to help combat drug overdoses, a California-based pharmaceutical company will extend a price cut for a heroin overdose antidote, reported The Wall Street Journal. Naloxone is a drug that can quickly reverse an opioid overdose and save lives. New York Attorney General Eric Schneiderman stated that drug maker Amphastar Pharmaceuticals will continue to offer a $6 per dose rebate through January 2018.

A think tank report has warned that Brexit could cause British patients to lose access to modern medicines, according to The New York Times. Currently, drug manufacturers use the European Medicine Agency to get drugs licensed across Europe. However, this system is likely to be dropped if Britain severs EU ties, the Times reported. “The results of ‘hard Brexit’ would not only be a sick economy but sick patients unable to access a cure,” stated the Public Policy Projects report. If Britain is cut from the European system, it could result in British patients being put at the back of the line for new drugs, because priority would be given to applications for new licenses from Europe.

In rare cases, checkpoint inhibitors used to treat cancer may cause patients to develop heart problems, reported The New York Times. Although less than 1% of patients who took these drugs have developed heart trouble, the damage can be severe, and have led to several deaths due to the immune system attacking the heart. The risk appears to be highest in patients who take 2 different checkpoint inhibitors at once, the Times reported.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com
Related Content
Advertisement
Op-Ed: Expand Patient Choice to Lower Medication Costs
June 6th 2025

Op-Ed: Expand Patient Choice to Lower Medication Costs

Colin Edgerton, MD
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
June 6th 2025

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Scan of breast cancer -- Image credit: Science RF | stock.adobe.com
June 5th 2025

ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

Gillian McGovern, Associate Editor
ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial
June 5th 2025

ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial

Vincent Chung, MD Alana Hippensteele, Lead Editor
Related Content
Advertisement
Op-Ed: Expand Patient Choice to Lower Medication Costs
June 6th 2025

Op-Ed: Expand Patient Choice to Lower Medication Costs

Colin Edgerton, MD
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
June 6th 2025

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Scan of breast cancer -- Image credit: Science RF | stock.adobe.com
June 5th 2025

ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

Gillian McGovern, Associate Editor
ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial
June 5th 2025

ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial

Vincent Chung, MD Alana Hippensteele, Lead Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.